Top 10 Companies in the Cyclopropanemethyl Ketone (CPMK) Market (2026): Market Leaders Powering Global Chemistry

MARKET INSIGHTS

Global Cyclopropanemethyl Ketone (CPMK) market size was valued at USD 18 million in 2024 and is projected to reach USD 27 million by 2032, exhibiting a CAGR of 5.7% during the forecast period (2025-2032). The U.S. accounted for a significant market share in 2024, while China is expected to witness accelerated growth due to expanding pharmaceutical and agrochemical sectors.

CPMK is a highly flammable, colorless liquid primarily used as a chemical intermediate. In pharmaceutical applications, it serves as a key precursor for synthesizing cyclopropacetylene – a critical component in antiretroviral drugs like efavirenz used in HIV/AIDS treatment. The pesticide industry utilizes CPMK for manufacturing advanced fungicides including cyprodinil and cyproconazole, driving demand in agricultural markets.

The market growth is fueled by increasing global healthcare expenditure, particularly in developing nations, coupled with rising demand for crop protection chemicals. Pharmaceutical‑grade CPMK currently dominates product segments due to stringent quality requirements for drug manufacturing. Leading players like Bayer, BASF, and Mitsubishi Chemical are expanding production capacities to meet growing demand, particularly in Asia‑Pacific regions where pharmaceutical and agrochemical industries are experiencing rapid expansion.

Cyclopropanemethyl Ketone (CPMK) Market – View in Detailed Research Report

Top 10 Companies in the Cyclopropanemethyl Ketone (CPMK) Market

1. BASF SE

   Headquarters: Ludwigshafen, Germany
   Key Offering: Pharmaceutical‑grade CPMK, specialty chemicals for agro‑industry

   BASF SE is a global chemical leader with extensive production facilities and a robust distribution network. The company’s CPMK production is integrated into its advanced synthesis lines, ensuring high purity and compliance with regulatory standards. BASF’s recent investment in a new purification plant in China aims to support the expanding demand for pharmaceutical intermediates in Asia‑Pacific.

   Sustainability & Growth Initiatives:

   • Launch of a green synthesis route reducing CO2 emissions by 20%.
   • Strategic partnership with a leading Chinese pharma to supply CPMK for antiretroviral drug manufacturing.
   • Investment in digital supply‑chain monitoring to improve traceability.

2. Bayer AG

   Headquarters: Leverkusen, Germany
   Key Offering: High‑purity CPMK for pharmaceutical and agrochemical applications

   Bayer AG leverages its expertise in agrochemicals and pharmaceuticals to produce CPMK at scale. The company’s integrated production lines in the U.S. and Europe ensure consistent quality for drug manufacturers. Bayer’s recent capacity expansion in Shanghai is aimed at meeting the surging demand for CPMK in the Chinese market.

   Sustainability & Growth Initiatives:

   • Implementation of a closed‑loop water system in its U.S. plant.
   • Collaboration with a German university to develop a bio‑based precursor for CPMK.
   • Target to reduce energy consumption by 15% by 2030.

3. TCI Chemicals

   Headquarters: Tokyo, Japan
   Key Offering: Fine‑chemical grade CPMK for pharmaceutical synthesis

   TCI Chemicals specializes in high‑purity intermediates for the pharmaceutical sector. Their CPMK is widely used in the synthesis of antiretroviral drugs and other specialty chemicals. TCI’s recent launch of a new production line in Singapore supports its global supply network.

   Sustainability & Growth Initiatives:

   • Adoption of renewable energy sources for its Singapore facility.
   • Development of a low‑toxicity solvent system for CPMK purification.
   • Partnership with a Japanese pharma to supply CPMK for a new HIV treatment.

4. Daicel Corporation

   Headquarters: Tokyo, Japan
   Key Offering: Pharmaceutical‑grade CPMK and specialty intermediates

   Daicel Corporation has achieved significant growth in its fine‑chemical segment, reporting 12% year‑over‑year growth in 2023. The company’s CPMK is recognized for its exceptional purity, making it a preferred choice for drug manufacturers worldwide.

   Sustainability & Growth Initiatives:

   • Implementation of an advanced catalytic process reducing solvent usage by 25%.
   • Collaboration with a Korean university to explore new CPMK derivatives.
   • Investment in a new plant in Osaka to increase production capacity by 30%.

5. Mitsubishi Chemical Group

   Headquarters: Tokyo, Japan
   Key Offering: CPMK for pharmaceuticals and agrochemicals

   Mitsubishi Chemical is expanding its backward integration into raw‑material sourcing, securing supply chains for its CPMK production. The company’s new facility in Shenzhen focuses on high‑purity intermediates for the Chinese market.

   Sustainability & Growth Initiatives:

   • Launch of a waste‑heat recovery system to cut emissions.
   • Partnership with a Chinese agrochemical firm to supply CPMK for fungicide production.
   • Investment in AI‑driven process optimization.

6. Ashland Global Holdings

   Headquarters: St. Louis, U.S.
   Key Offering: Pharmaceutical‑grade CPMK and specialty chemicals

   Ashland Global Holdings serves the U.S. pharmaceutical market with high‑purity CPMK. The company’s focus on quality and regulatory compliance has positioned it as a trusted supplier for major drug manufacturers.

   Sustainability & Growth Initiatives:

   • Implementation of a zero‑liquid‑discharge policy in its U.S. plant.
   • Collaboration with a U.S. biotech firm to develop CPMK‑based drug candidates.
   • Investment in a new plant in Texas to increase capacity by 20%.

7. SANKYO CHEMICAL

   Headquarters: Tokyo, Japan
   Key Offering: CPMK for pharmaceutical and agrochemical applications

   SANKYO CHEMICAL announced capacity expansion plans targeting European markets. The company’s CPMK is used in the synthesis of advanced fungicides and antiretroviral drugs.

   Sustainability & Growth Initiatives:

   • Adoption of a bio‑based catalyst to reduce CO2 emissions.
   • Partnership with a German pharma to supply CPMK for HIV treatment.
   • Investment in a new plant in Rotterdam to serve the EU market.

8. SINO‑JAPAN CHEMICAL

   Headquarters: Shanghai, China
   Key Offering: CPMK for agrochemical and pharmaceutical use

   SINO‑JAPAN CHEMICAL has become a key player in China’s CPMK market, controlling a significant share of production capacity. The company focuses on cost‑effective production while maintaining quality standards.

   Sustainability & Growth Initiatives:

   • Implementation of a water‑recycling system in its Shanghai plant.
   • Collaboration with a Chinese university to develop new CPMK derivatives.
   • Investment in a new facility in Suzhou to increase output by 25%.

9. DSM Nutritional Products

   Headquarters: Wageningen, Netherlands
   Key Offering: Pharmaceutical‑grade CPMK and fine chemicals

   DSM Nutritional Products patented an improved synthesis method for CPMK in Q2 2023, enhancing purity and reducing waste. The company’s CPMK is widely used in drug manufacturing and agrochemical production.

   Sustainability & Growth Initiatives:

   • Launch of a green chemistry program reducing solvent use by 30%.
   • Partnership with a Dutch pharma to supply CPMK for antiretroviral drugs.
   • Investment in a new plant in Rotterdam to meet European demand.

10. Janssen Pharmaceutica

    Headquarters: Beerse, Belgium
    Key Offering: CPMK for pharmaceutical synthesis

    Janssen Pharmaceutica is a major consumer of high‑purity CPMK for the synthesis of antiretroviral drugs. The company’s focus on innovation has driven demand for advanced intermediates.

    Sustainability & Growth Initiatives:

    • Implementation of a closed‑loop system in its production facilities.
    • Collaboration with a Belgian university to develop new CPMK‑based drug candidates.
    • Investment in a new plant in Ghent to increase capacity by 15%.

Download FREE Sample Report

Get Full Report

Outlook

Global CPMK demand is expected to grow steadily, driven by expanding pharmaceutical and agrochemical sectors. The market is projected to reach USD 27 million by 2032, with a CAGR of 5.7% from 2025 to 2032. Asia‑Pacific will remain the fastest‑growing region, while North America will maintain a strong presence due to its mature pharmaceutical market.

Future Trends

• Adoption of green synthesis methods to reduce environmental impact.
• Increased investment in R&D for novel CPMK derivatives with potential therapeutic applications.
• Expansion of supply chains in Asia‑Pacific to meet rising demand for pharmaceutical‑grade CPMK.
• Growth of digital supply‑chain solutions to enhance traceability and compliance.